Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP for type 3 pulmonary hypertension
ChiCTR2200065596Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nesiritide in pulmonary hypertension (PH) (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Mean pulmonary artery pressure. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on ChiCTR2200065596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065596.